Literature DB >> 1430301

Circadian changes of valproate kinetics depending on meal condition in humans.

S Ohdo1, S Nakano, N Ogawa.   

Abstract

The objective of this study was to examine the effect of meal condition on circadian changes in valproic acid (VPA) kinetics. Two experiments were performed in 16 healthy men that were synchronized with diurnal activity and nocturnal rest as their routine life. In both experiments, four 200-mg tablets of VPA were given orally on two occasions in the morning (8:30 AM) or in the evening (8:30 PM). In each study, a randomized, single-dose, two-way crossover design was used, and 2 weeks elapsed between morning and evening trials. In experiment 1, eight subjects took a light meal as breakfast between 8:00 and 8:15 AM and a heavy meal as dinner between 6:00 and 6:30 PM to fit the subject's usual food amount. The mean peak plasma concentration (Cmax) was significantly higher (P less than .01), the time to peak concentration (tmax) was shorter (P less than .05), and the absorption rate (Ka) was larger (P less than .05) after the morning dose than after the evening dose. In experiment 2, the size and contents of meal in breakfast and dinner were prepared in the same manner as the standard breakfast for the subjects. Namely, eight subjects took the same light meal between 8:00 and 8:15 AM in the morning and between 8:00 and 8:15 PM in the evening. There was no significant circadian change in VPA kinetics under this same meal condition. These results suggest that the differences of meal condition between morning and evening in our daily life play a major role in the mechanism underlying the circadian changes of VPA absorption in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430301     DOI: 10.1002/j.1552-4604.1992.tb03889.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Chronopharmacokinetics. Current status.

Authors:  B Bruguerolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

3.  Chronopharmacology of intravenous and oral modified release verapamil.

Authors:  K Dilger; K Eckhardt; U Hofmann; K Kucher; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 4.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

5.  Divalproex to divalproex extended release conversion.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

6.  Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.

Authors:  Todd M Conner; Vahagn C Nikolian; Patrick E Georgoff; Manjunath P Pai; Hasan B Alam; Duxin Sun; Ronald C Reed; Tao Zhang
Journal:  Eur J Pharm Sci       Date:  2017-10-10       Impact factor: 4.384

Review 7.  Chronopharmacology of anti-convulsive therapy.

Authors:  Sriram Ramgopal; Sigride Thome-Souza; Tobias Loddenkemper
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.